Pharmacodynamics of mitomycin C in cultured human bladder tumors.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 1906778)

Published in Cancer Res on August 01, 1991

Authors

T D Schmittgen1, M G Wientjes, R A Badalament, J L Au

Author Affiliations

1: College of Pharmacy, Ohio State University, Columbus 43210.

Articles by these authors

Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst (2001) 2.82

Penile cancer. Clinical presentation, diagnosis, and staging. Urol Clin North Am (1992) 1.47

Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. J Urol (1989) 1.42

Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas. Cancer Invest (2001) 1.40

Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther (1999) 1.32

Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A (2000) 1.32

Determinants of drug delivery and transport to solid tumors. J Control Release (2001) 1.24

Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther (2001) 1.20

Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther (2000) 1.16

Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res (1998) 1.15

Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res (1982) 1.14

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol (1988) 1.11

The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer (1987) 1.10

Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci (2001) 1.06

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol (1987) 1.03

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol (1989) 1.00

Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther (2001) 0.97

Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res (2001) 0.94

Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther (2001) 0.94

Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs (2001) 0.94

Coumarin necrosis of the penis. J Urol (1989) 0.93

Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res (2001) 0.92

Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol (1999) 0.92

Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res (1991) 0.90

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 0.90

Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res (1991) 0.90

Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res (1998) 0.89

Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats. Antimicrob Agents Chemother (1992) 0.88

A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharm Res (1991) 0.88

Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis. AAPS PharmSci (1999) 0.88

Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol (1997) 0.88

Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep (1979) 0.86

Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob Agents Chemother (1994) 0.86

Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors. Pharm Res (1998) 0.86

Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol (1998) 0.86

Extraction of intracellular nucleosides and nucleotides with acetonitrile. Clin Chem (1989) 0.86

Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res (1998) 0.86

2',3'-Dideoxyinosine is not metabolized in human placenta. Drug Metab Dispos (1993) 0.85

Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res (1998) 0.85

Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Pharm Res (1998) 0.84

Pharmacodynamics of taxol in human head and neck tumors. Cancer Res (1996) 0.84

Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol (1993) 0.84

Penetration of mitomycin C in human bladder. Cancer Res (1993) 0.84

Voided urine flow cytometry in screening high-risk patients for the presence of bladder cancer. J Occup Med (1990) 0.84

Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in rats. J Pharmacol Exp Ther (1993) 0.83

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol (2008) 0.83

Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer (1995) 0.83

Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Appl (1995) 0.83

Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry (1993) 0.83

Telomere amount and length assay. Pharm Res (2001) 0.82

A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol (2000) 0.82

Conservative management of epidermoid cyst of testis. Urology (1986) 0.82

Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res (1996) 0.81

Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up. Anticancer Res (1997) 0.81

Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum. Pharm Res (1993) 0.81

Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res (1996) 0.81

Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res (1995) 0.81

Effect of interstitial cystitis on drug absorption from urinary bladder. J Pharmacol Exp Ther (1994) 0.80

Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol (1994) 0.80

Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res (1978) 0.80

Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci (1996) 0.80

Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol (1999) 0.80

Pharmacokinetics of oral 2',3'-dideoxyinosine in rats. Pharm Res (1992) 0.80

Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol (1996) 0.80

Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Clin Cancer Res (1997) 0.80